Aribiolab

At a glance

Aribiolab filed 79 disclosures in the last 12 months, including 10 5% holder, 6 issuance and 2 insider. The most recent key filing was on Sep 16: A major holder's stake rose from 20.69% to 20.69% (pledge).

Revenue for 2025 was ₩158.6M, down 57.2% on 2024. It made an operating loss of ₩14.3B. Debt was 151% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩173.2M and operating loss of ₩4.2B.

The 2025 annual report lists 49 employees with an average tenure of 3.8 years and average pay of ₩63.4M. Its 5 directors and auditors were paid ₩49M each on average. It paid no cash dividend for 2025. ㈜차바이오텍 and related parties held 39.34% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 2 cut a stake; the largest stake reported was 20.69% on Sep 16.

From the 2025 annual report

Staff: 49 (14 men, 35 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 5, paid ₩243M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜차바이오텍 holds 38.30%; with 3 related parties the group holds 39.34% of common shares at year end (from 39.29% at the start of the year).

Auditor: 서우회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports